Molecular Oncology
Volume 4, Issue 3 , Pages 174-191 , June 2010

Genetic susceptibility to breast cancer

  • Nasim Mavaddat

      Affiliations

    • Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom
    • ,
  • Antonis C. Antoniou

      Affiliations

    • Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom
    • ,
  • Douglas F. Easton

      Affiliations

    • Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom
    • ,
  • Montserrat Garcia-Closas

      Affiliations

    • Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom
    • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville MD, United States
    • Corresponding Author InformationCorresponding author. Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, United Kingdom. Tel.: +44 1223740145; fax: +44 1223740147.

Received 8 March 2010 ,Revised 29 April 2010 ,Accepted 29 April 2010.

References 

  1. van ’t Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  2. Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M, Schlessinger J, et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene. 1991;6:659–663
  3. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 2009;41:585–590
  4. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 2006;66:8327–8330
  5. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. 2004;1:e65;229–236
  6. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res. Treat. 2002;76:27–36
  7. Anderson WF, Matsuno R. Breast cancer heterogeneity: a mixture of at least two main types?. J. Natl. Cancer Inst. 2006;98:948–951
  8. Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J. Natl. Cancer Inst. 2006;98:535–544
  9. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene. 2006;25:5898–5905
  10. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br. J. Cancer. 2002;86:76–83
  11. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 2003;72:1117–1130
  12. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br. J. Cancer. 2004;91:1580–1590
  13. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet. 2007;81:1186–1200
  14. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br. J. Cancer. 2008;98:1457–1466
  15. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet. 2008;82:937–948
  16. Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 2009;18:4442–4456
  17. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998;83:2335–2345
  18. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999;59:2011–2017
  19. Barnhart BC, Lee JC, Alappat EC, Peter ME. The death effector domain protein family. Oncogene. 2003;22:8634–8644
  20. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol. Oncol. 2008;2:296–316
  21. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J. Natl. Cancer Inst. 2002;94:1221–1226
  22. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299:194–201
  23. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20:4621–4628
  24. de Bock GH, Mourits MJ, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, et al. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status. Int. J. Gynecol. Cancer. 2006;16(Suppl. 2):552–555
  25. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 2006, 98:1382–1396.
  26. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295:2492–2502
  27. Cavdar KE, Burkhart W, Blackburn K, Moseley A, Spremulli LL. The small subunit of the mammalian mitochondrial ribosome. Identification of the full complement of ribosomal proteins present. J. Biol. Chem. 2001;276:19363–19374
  28. Cavdar KE, Ranasinghe A, Burkhart W, Blackburn K, Koc H, Moseley A, et al. A new face on apoptosis: death-associated protein 3 and PDCD9 are mitochondrial ribosomal proteins. FEBS Lett. 2001;492:166–170
  29. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004, 74:1175–1182.
  30. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 1999;59:1752s–1756s
  31. Chen Y, Choong LY, Lin Q, Philp R, Wong CH, Ang BK, et al. Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol. Cell Proteomics. 2007;6:2072–2087
  32. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J. Natl. Cancer Inst. 2005;97:439–448
  33. Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res. Treat. 2002;74:199–211
  34. Clayton DG. Prediction and interaction in complex disease genetics: experience in type 1 diabetes. PLoS Genet. 2009;5:e1000540;1–6
  35. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J. Natl. Cancer Inst. 2004;96:218–228
  36. Cortesi L, Turchetti D, Bertoni C, Bellei R, Mangone L, Vinceti M, et al. Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. Genes Chromosomes Cancer. 2000;27:130–135
  37. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol. Biomarkers Prev. 2003;12:1053–1060
  38. Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-Lyonnet D, et al. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol. Biomarkers Prev. 2007;16:1416–1421
  39. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 2007;39:352–358
  40. Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int. J. Cancer. 2005;117:988–991
  41. Cunningham, J.E., Montero, A.J., Garrett-Mayer, E., Berkel, H.J., Ely, B, 2009. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control.
  42. Cybulski C, Wokolorczyk D, Gliniewicz B, Sikorski A, Gorski B, Jakubowska A, et al. A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res. Treat. 2008;112:367–368
  43. Cybulski C, Huzarski T, Byrski T, Gronwald J, Debniak T, Jakubowska A, et al. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin. Genet. 2009;75:72–78
  44. De VG, Verderio P, Pizzamiglio S, Manoukian S, Barile M, Fortuzzi S, et al. Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. Breast Cancer Res. Treat. 2009;113:607–608
  45. Dickson C, Spencer-Dene B, Dillon C, Fantl V. Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res. 2000;2:191–196
  46. Easton DF. Familial risks of breast cancer. Breast Cancer Res. 2002;4:179–181
  47. Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum. Mol. Genet. 2008;17:R109–R115
  48. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1993;52:678–701
  49. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–1093
  50. Eisinger F, Nogues C, Guinebretiere JM, Peyrat JP, Bardou VJ, Noguchi T, et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int. J. Cancer. 1999;84:263–267
  51. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease, 2001. Lancet, 358, 1389–1399.
  52. Fejerman L, Haiman CA, Reich D, Tandon A, Deo RC, John EM, et al. An admixture scan in 1484 African American women with breast cancer. Cancer Epidemiol. Biomarkers Prev. 2009;18:3110–3117
  53. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1998;62:676–689
  54. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 2004;10:2029–2034
  55. Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, et al. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res. Treat. 2008;111:139–144
  56. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin. Breast Cancer. 2007;7:875–882
  57. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett. 2009;281:128–133
  58. Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J. Natl. Cancer Inst. 2009;101:959–963
  59. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 1991;51:6094–6097
  60. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin. Cancer Res. 2008;14:8000–8009
  61. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br. J. Cancer. 2006;95:123–129
  62. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008;4:e1000054;1–10.
  63. Ghoussaini M, Pharoah PD. Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol. 2009;5:689–701
  64. Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl. Acad. Sci. USA. 2008;105:4340–4345
  65. Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH, Le ML. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat. Genet. 2008;40:259–260
  66. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684–1689
  67. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 2001;93:1633–1637
  68. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 2001;344:539–548
  69. Heikkinen T, Karkkainen H, Aaltonen K, Milne RL, Heikkila P, Aittomaki K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin. Cancer Res. 2009;15:3214–3222
  70. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998;391:184–187
  71. Hines LM, Risendal B, Slattery ML, Baumgartner KB, Giuliano AR, Byers T. Differences in estrogen receptor subtype according to family history of breast cancer among Hispanic, but not non-Hispanic White women. Cancer Epidemiol. Biomarkers Prev. 2008;17:2700–2706
  72. Hishikawa Y, Tamaru N, Ejima K, Hayashi T, Koji T. Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch. Histol. Cytol. 2004;67:455–464
  73. Hopper JL, Carlin JB. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am. J. Epidemiol. 1992;136:1138–1147
  74. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606–609
  75. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am. J. Epidemiol. 2000;151:703–714
  76. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 1998;18:38–43
  77. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer. 1997;33:362–371
  78. Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, et al. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res. Treat. 2009;117:371–379
  79. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res. Treat. 2002;73:45–59
  80. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997;80:435–441
  81. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J. Clin. Oncol. 2008;26:1331–1337
  82. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 2002;94:606–616
  83. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646
  84. Kirchhoff T, Chen ZQ, Gold B, Pal P, Gaudet MM, Kosarin K, et al. The 6q22.33 locus and breast cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 2009;18:2468–2475
  85. Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher S, et al. Parental origin of sequence variants associated with complex diseases. Nature. 2009;462:868–874
  86. Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum. Mol. Genet. 2002;11:1399–1407
  87. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol. Oncol. 2010;4(3):255–266
  88. Lakhani SR. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res. 1999;1:31–35
  89. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, Van De Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 1998;90:1138–1145
  90. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, Van De Vijver MJ, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin. Cancer Res. 2000;6:782–789
  91. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 2002;20:2310–2318
  92. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Cancer Res. 2004;10:2473–2481
  93. Lidereau R, Eisinger F, Champeme MH, Nogues C, Bieche I, Birnbaum D, et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 2000;60:1206–1210
  94. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 1998;83:310–319
  95. Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br. J. Cancer. 1992;66:273–280
  96. Lønning PE. Molecular basis for therapy resistance. Mol. Oncol. 2010;4(3):284–300
  97. Malkin D. Germline p53 mutations and heritable cancer. Annu. Rev. Genet. 1994;28:443–465
  98. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, et al. Germline E-cadherin mutations in familial lobular breast cancer. J. Med. Genet. 2007;44:726–731
  99. Mavaddat N, Dunning AM, Ponder BA, Easton DF, Pharoah PD. Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2009;18:255–259
  100. Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, Thompson D, et al. Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res. 2010;12:R10;1--2
  101. Meijers-Heijboer H, van GB, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001;345:159–164
  102. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de SA, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 2002;31:55–59
  103. Meyer KB, Maia AT, O’Reilly M, Teschendorff AE, Chin SF, Caldas C, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 2008;6:e108
  104. Milne RL, Benitez J, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, et al. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J. Natl. Cancer Inst. 2009;101:1012–1018
  105. Milne RL, Osorio A, Cajal T, Baiget M, Lasa A, Diaz-Rubio E, et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 2010;119:221–232
  106. Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol. Cancer Res. 2004;2:643–652
  107. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat. Rev. Cancer. 2002;2:113–123
  108. Navin NE, Hicks J. Tracing the tumor lineage. Mol. Oncol. 2010;4(3):267–283
  109. Nelen MR, Padberg GW, Peeters EA, Lin AY, van den Helm B, Frants RR, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat. Genet. 1996;13:114–116
  110. O’Flaherty E, Kaye J. TOX defines a conserved subfamily of HMG-box proteins. BMC Genomics. 2003;4:13-
  111. Osin PP, Lakhani SR. The pathology of familial breast cancer: immunohistochemistry and molecular analysis. Breast Cancer Res. 1999;1:36–40
  112. Osorio A, de la Hoya M, Rodriguez-Lopez R, Martinez-Ramirez A, Cazorla A, Granizo JJ, et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int. J. Cancer. 2002;99:305–309
  113. Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, et al. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br. J. Cancer. 2009;101:2048–2054
  114. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin. Cancer Res. 2003;9:3606–3614
  115. Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. vol. VIII. 2002;
  116. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium, 1997. Lancet, 349, 1505–1510.
  117. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  118. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet. 2000;26:411–414
  119. Pharoah PD, Lipscombe JM, Redman KL, Day NE, Easton DF, Ponder BA. Familial predisposition to breast cancer in a British population: implications for prevention. Eur. J. Cancer. 2000;36:773–779
  120. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 2002;31:33–36
  121. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med. 2008;358:2796–2803
  122. Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J. Clin. Oncol. 2000;18:107S–112S
  123. Podo F, Buydens LMC, Degani H, Hilhorst R, Klipp E, Gribbestad IS, et al. Triple-negative breast cancer: Present challenges and new perspectives. Mol. Oncol. 2010;4(3):209–229
  124. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa women’s health study: how many kinds of breast cancer are there?. Cancer Epidemiol. Biomarkers Prev. 1995;4:319–326
  125. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 2007;39:165–167
  126. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 2002;346:1616–1622
  127. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ’ V, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 2004;22:1055–1062
  128. Rebbeck TR, Antoniou AC, Llopis TC, Nevanlinna H, Aittomaki K, Simard J, et al. No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Res. Treat. 2009;115:185–192
  129. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 2009;101:80–87
  130. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 2006;38:873–875
  131. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40:1365–1385
  132. Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2006;15:2482–2488
  133. Ruiz-Narvaez EA, Rosenberg L, Rotimi CN, Cupples LA, Boggs DA, Adeyemo A, et al. Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the black women’s health study. Breast Cancer Res. Treat. 2010;
  134. Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev. 2005;29:419–426
  135. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88:265–275
  136. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 2006;38:1239–1241
  137. Surveillance, Epidemiology, and End Results (SEER) Program Limited-Use Data (1973–2006), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Released April 2009, based on the November 2008 submission. <www.seer.cancer.gov> 9 A.D
  138. Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, et al. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int. J. Cancer. 2007;121:1079–1085
  139. Sinilnikova OM, Antoniou AC, Simard J, Healey S, Leone M, Sinnett D, et al. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br. J. Cancer. 2009;101:1456–1460
  140. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, et al. Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 2006;24:2261–2267
  141. Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM, Newman B, et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer. 2006;45:646–655
  142. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet. 2009;41:996–1000
  143. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U S A. 2003;100:8418–8423
  144. Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, et al. The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 2006;15:76–79
  145. Spurdle AB, Deans AJ, Duffy D, Goldgar DE, Chen X, Beesley J, et al. No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 2009;115:307–313
  146. Spurdle AB, Fahey P, Chen X, McGuffog L, Easton D, Peock S, et al. Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 2009;
  147. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 2007;39:865–869
  148. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 2008;40:703–706
  149. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat. Genet. 2007;39:605–613
  150. Tamaru N, Hishikawa Y, Ejima K, Nagasue N, Inoue S, Muramatsu M, et al. Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab. Invest. 2004;84:1460–1471
  151. Teo YY, Small KS, Kwiatkowski DP. Methodological challenges of genome-wide association analysis in Africa. Nat. Rev. Genet. 2010;11:149–160
  152. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 2009;41:579–584
  153. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet. 2001;68:410–419
  154. Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol. Biomarkers Prev. 2002;11:329–336
  155. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J. Mammary Gland Biol. Neoplasia. 2004;9:221–236
  156. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu. Rev. Genomics Hum. Genet. 2008;9:321–345
  157. Tutera AM, Sellers TA, Potter JD, Drinkard CR, Wiesner GL, Folsom AR. Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status. Genet. Epidemiol. 1996;13:207–221
  158. Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, et al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum. Mol. Genet. 2009;18:1692–1703
  159. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, et al. Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 2010;362:986–993
  160. Webb PM, Hopper JL, Newman B, Chen X, Kelemen L, Giles GG, et al. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2005;14:319–323
  161. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: How special are they?. Mol. Oncol. 2010;4(3):192–208
  162. Welsh ML, Buist DS, Aiello Bowles EJ, Anderson ML, Elmore JG, Li CI. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res. Treat. 2009;114:549–558
  163. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J. Biol. Chem. 1997;272:31941–31944
  164. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088–2090
  165. Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA, et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res. 2007;67:10608–10617
  166. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol. Med. 2006;12:537–544
  167. Zang XP, Pento JT. Keratinocyte growth factor-induced motility of breast cancer cells. Clin. Exp. Metastasis. 2000;18:573–580
  168. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 2008;40:638–645
  169. Zhang Y, Kulp SK, Sugimoto Y, Farrar WB, Brueggemeier RW, Lin YC. Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells. Anticancer Res. 1998;18:2541–2546
  170. Zhang Y, Sugimoto Y, Kulp SK, Farrar WB, Brueggemeier RW, Lin YC. Estrogen-induced keratinocyte growth factor mRNA expression in normal and cancerous human breast cells. Oncol. Rep. 1998;5:577–583
  171. Zheng W, Cai Q, Signorello LB, Long J, Hargreaves MK, Deming SL, et al. Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol. Biomarkers Prev. 2009;18:2761–2764
  172. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet. 2009;41:324–328

PII: S1574-7891(10)00033-5

doi: 10.1016/j.molonc.2010.04.011

Molecular Oncology
Volume 4, Issue 3 , Pages 174-191 , June 2010

Article Tools

* Image Usage & Resolution